Lyme Disease: Knowing Good Evidence to Help Inform Practice

Auwaerter, Paul G.

doi:10.1016/j.idc.2015.03.001

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lyme disease (LD) is the most commonly reported vector-borne disease in North America, caused by the spirochetal bacterium, Borrelia burgdorferi , which is transmitted from black-legged ticks [ 1 ]. In Canada, the annual number of LD cases has increased from 144 in 2009 to 2,636 in 2019 (18-fold increase) [ 2 ], and in Canada’s most populous province (Ontario), the incidence rate has increased from 0.7 per 100,000 in 2010 to 7.9 per 100,000 persons in 2019 [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Healthcare costs and outcomes associated with laboratory-confirmed Lyme disease in Ontario, Canada: A population-based cohort study

et al. 2023

View full text Add to dashboard Cite

Background The objective of this study was to estimate the economic burden attributable to laboratory-confirmed Lyme disease (LD) in Ontario, Canada and assess health outcomes associated with LD. Method We conducted a cohort study using laboratory-confirmed LD cases accrued between 2006 and 2018. The exposed cohort was matched 1:3 to the unexposed cohort using a combination of hard and propensity score matching. We used phase-of-care costing methods to calculate attributable costs for four phases of illness: pre-diagnosis, acute care, post-acute care, and continuing care in 2018 Canadian dollars. We used ICD-10-CA and OHIP billing codes to identify emergency department visits, physician billings and hospitalizations related to LD sequelae to assess health outcomes. Results A total of 2,808 cases were identified with a mean age of 46.5 (20.7) years and 44% female. Within 30-days, 404 (14.3%) cases required an ED visit and 63 (2.4%) cases required hospitalization. The mean (95% CI) total costs for LD cases in pre-diagnosis, acute, and post-acute care phases were $209 ($181, 238), $1,084 ($956, $1,212), and $1,714 ($1,499, $1,927), respectively. The highest mean attributable 10-day cost was $275 ($231, $319) during acute care. At 1-year post-infection, LD increased the relative risk of nerve palsies by 62 (20, 197), and polyneuropathy by 24 (3.0, 190). LD resulted in 16 Lyme meningitis events vs. 0 events in the unexposed. Conclusion Individuals with laboratory-confirmed LD have increased healthcare resource use pre-diagnosis and up to six months post-diagnosis, and were more likely to seek healthcare services related to LD sequelae.

show abstract

Section: Introductionmentioning

confidence: 99%